Grown Rogue International (GRUSF) Cash from Financing Activities (2013 - 2026)
Grown Rogue International (GRUSF) posted quarterly Cash from Financing Activities of $2.7 million for Q1 2026, down 41.3% year-over-year from $4.5 million in Q1 2025, and up 100.0% quarter-over-quarter from -$10136.9 billion in Q4 2025.
Grown Rogue International (GRUSF) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Grown Rogue International's Cash from Financing Activities history runs 14 years deep, the most recent figure standing at $2.7 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 41.3% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at -$10136.9 billion (down 299677217.61% YoY), while the FY2025 annual figure was $9.8 million, up 117.4% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $2.7 million, up from -$10136.9 billion in the prior quarter.
- The five-year high for Cash from Financing Activities was $4.5 million in Q1 2025, with the low at -$10136.9 billion in Q4 2025.
- The 5-year median for Cash from Financing Activities is $797962.1 (2023), against an average of -$779.8 billion.
- Peak annual rise in Cash from Financing Activities reached 54.82% in 2025, while the deepest fall reached 3604482049.28% in 2025.
- Grown Rogue International's Cash from Financing Activities stood at $944368.0 in 2022, then soared by 162.2% to $2.5 million in 2023, then slumped by 111.36% to -$281230.6 in 2024, then slumped by 3604482049.28% to -$10136.9 billion in 2025, then soared by 100.0% to $2.7 million in 2026.
- Business Quant data shows GRUSF's Cash from Financing Activities at $2.7 million in Q1 2026, -$10136.9 billion in Q4 2025, and -$308664.9 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Grown Rogue International | 109.32 Mn | 97.78 Mn | 5.37 Mn | -464,614.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -464,614.00 |
| Jun 30, 2026 | -464,614.00 |
| Mar 31, 2026 | 2.67 Mn |
| Mar 31, 2026 | 2.67 Mn |
| Dec 31, 2025 | -10,136.91 Bn |
| Dec 31, 2025 | -10,136.91 Bn |
| Jun 30, 2025 | -308,664.89 |
| Jun 30, 2025 | -308,664.89 |
| Mar 31, 2025 | 4.55 Mn |
| Mar 31, 2025 | 4.55 Mn |
| Dec 31, 2024 | -281,230.64 |
| Dec 31, 2024 | -281,230.64 |
| Sep 30, 2024 | -200,531.89 |
| Sep 30, 2024 | -200,531.89 |
| Jun 30, 2024 | -683,206.97 |
| Jun 30, 2024 | -683,206.97 |
| Mar 31, 2024 | 3.38 Mn |
| Mar 31, 2024 | 3.38 Mn |
| Oct 31, 2023 | 2.48 Mn |
| Oct 31, 2023 | 2.48 Mn |